Insmed Inc. (INSM)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$126.29-0.31%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Insmed aims for $1 billion BRINSUPRI revenue in 2026. ARIKAYCE sales target $450-$470 million in 2026. The company is advancing new respiratory treatments. Recent earnings beat shows some progress.
Insmed is loss-making with negative free cash flow. Recent guidance was cut and competitive pressures are rising. Multiple earnings misses and litigation risks weigh on outlook.
The price is about 9% below our fair value near $124. Analysts expect nearly 94% revenue growth, but our fair value is 38% below the Street median, reflecting caution on profitability and risks.
Breaks if: ARIKAYCE revenue falls below $450M in FY26
Breaks if: BRINSUPRI revenue falls below $1B in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making but has shown strong revenue growth in its key products, which is crucial for its long-term prospects.
The market seems to have priced in a low level of fragility, suggesting that investors are not overly concerned about immediate risks. However, there is a notable expectations gap, indicating that the current valuation reflects a premium compared to peers.
Management has set ambitious revenue targets for its products, and recent performance has shown positive growth trends. However, the company operates in a high-miss-rate industry, which introduces some near-term risk despite a low probability of missing its guidance.
The thesis hinges on the company's ability to meet its revenue targets and the performance of its clinical trials. Additionally, broader sector trends, particularly the performance of leading healthcare companies, will play a significant role in shaping investor sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. Insmed expects $1.25 billion to $1.40 billion in BRINSUPRI revenue for 2026. The company is advancing the development of INS1148 for respiratory diseases.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Continue commercial expansion of BRINSUPRI with a full-year revenue target of at least $1 billion for 2026.
Breaks if: Development of INS1148 stalls or is discontinued
Breaks if: EPS remains negative through FY27
Over the next 1 to 3 years, INSM's trajectory will depend on its execution against growth targets and the overall healthcare market environment. Not investment advice.